FDA Expert Panel Backs Compounding of Six Peptides

An FDA advisory panel voted to recommend adding six unapproved peptides (BPC-157, KPV, TB-500, MOTS-c, epitalon, semax) to the 503A bulk compounding list, allowing pharmacists to produce them without safety or efficacy data. The move could legalise a growing grey-market practice, though FDA rulemaking and HHS Secretary Kennedy's discretion will determine whether compounding is formally permitted.

This Wire brief sits within Fusion42's coverage of Medtech. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.